A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who are starting basal insulin therapy for the first time.
Inclusion Criteria:
Exceptions:
Exclusion Criteria:
Springfield, Illinois 62711, United States
Troy, Michigan 48098, United States
North Richland Hills, Texas 76180, United States
Ciudad Autónoma de Buenos Aire, Buenos Aires 1056, Argentina
C.a.b.a., Ciudad Aut C1205AAO, Argentina
Ciudad Autonoma de Buenos Aire, Ciudad Autónoma de Buenos Aire C1425AGC, Argentina
Godoy Cruz, Mendoza Province M5501ARP, Argentina
Rosario, Santa Fe Province 2000, Argentina
Ciudad Autónoma de Buenos Aire, C1440AAD, Argentina